Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Not Applicable
Completed
Conditions
Insulin Sensitivity
Multiple Mitochondrial Dysfunctions Syndrome
Interventions
Drug: Placebo
Drug: Dapagliflozin
Subscribe
First Posted Date
2011-09-23
Last Posted Date
2019-10-29
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
18
Registration Number
NCT01439854
Locations
🇺🇸
Diabetes Division, UTHSCSA, San Antonio, Texas, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy